The FDA's Psychopharmacologic Drugs Advisory Committee voted 8-2 Wednesday in support of an expanded label for Takeda Pharmaceutical Co. Ltd.'s Brintellix (vortioxetine) that would recognize cognitive dysfunction in adults with major depressive disorder (MDD) as a distinct indication. Brintellix was approved in 2013 to treat MDD.